Synthetic lethality guiding selection of drug combinations in ovarian cancer

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast

(2018) Maximilian Marhold et al.   Oncotarget

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer

(2016) Peter Andorfer et al.   BMC Systems Biology

Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer

(2016) M. Hijaz et al.   GYNECOLOGIC ONCOLOGY

Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

(2016) Claudia Dallinger et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Genome-wide genetic screening with chemically mutagenized haploid embryonic stem cells

(2016) Josep V Forment et al.   Nature Chemical Biology

Nintedanib in NSCLC: evidence to date and place in therapy

(2016) Giuseppe Bronte et al.   Therapeutic Advances in Medical Oncology

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients

(2015) Katherine C. Fuh et al.   GYNECOLOGIC ONCOLOGY

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study

(2015) Didier Meulendijks et al.   INVESTIGATIONAL NEW DRUGS

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX

(2015) Yufeng Wang et al.   Targeted Oncology

Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer

(2015) Jessica A. Beach et al.   Oncotarget

Phase II Multicenter Study of Docetaxel and Bevacizumab With or Without Trastuzumab as First-Line Treatment for Patients With Metastatic Breast Cancer

(2014) Lee S. Schwartzberg et al.   Clinical Breast Cancer

Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes

(2014) Vassilis Papanikolaou et al.   CELLULAR ONCOLOGY

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study

(2013) C. Fotopoulou et al.   ANNALS OF ONCOLOGY

Database resources of the National Center for Biotechnology Information

(2013)   NUCLEIC ACIDS RESEARCH

Ensembl Genomes 2013: scaling up access to genome-wide data

(2013) Paul Julian Kersey et al.   NUCLEIC ACIDS RESEARCH

Data, information, knowledge and principle: back to metabolism in KEGG

(2013) Minoru Kanehisa et al.   NUCLEIC ACIDS RESEARCH

Roundup 2.0: enabling comparative genomics for over 1800 genomes

(2012) T. F. DeLuca et al.   BIOINFORMATICS

BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death

(2012) Chaitali Dutta et al.   CANCER RESEARCH

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

(2012) Michael J. Lee et al.   CELL

Synthetic lethality for linking the mycophenolate mofetil mode of action with molecular disease and drug profiles

(2012) Johannes Söllner et al.   Molecular BioSystems

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

(2011) Shiyu Zhang et al.   GYNECOLOGIC ONCOLOGY

InterPro in 2011: new developments in the family and domain prediction database

(2011) S. Hunter et al.   NUCLEIC ACIDS RESEARCH

Synthetic lethality: General principles, utility and detection using genetic screens in human cells

(2010) Sebastian M.B. Nijman   FEBS LETTERS

Selective Impairment of CD4+CD25+Foxp3+Regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis

(2010) Nan Liu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Synthetic lethal hubs associated with vincristine resistant neuroblastoma

(2010) Raul Fechete et al.   Molecular BioSystems

OMA 2011: orthology inference among 1000 complete genomes

(2010) A. M. Altenhoff et al.   NUCLEIC ACIDS RESEARCH

The Genetic Landscape of a Cell

(2010) M. Costanzo et al.   SCIENCE

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Gene Characterization Index: Assessing the Depth of Gene Annotation

(2008) Danielle Kemmer et al.   PLoS One